| 000 | 01859 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518092932.0 | ||
| 264 | 0 | _c20210419 | |
| 008 | 202104s 0 0 eng d | ||
| 022 | _a2056-5933 | ||
| 024 | 7 |
_a10.1136/rmdopen-2019-001149 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHelliwell, Philip S | |
| 245 | 0 | 0 |
_aEffects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. _h[electronic resource] |
| 260 |
_bRMD open _c02 2020 |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Psoriatic _xcomplications |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHLA-B27 Antigen _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterleukin-12 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhysicians _xstatistics & numerical data |
| 650 | 0 | 4 |
_aPlacebos _xadministration & dosage |
| 650 | 0 | 4 |
_aSpondylitis _xdrug therapy |
| 650 | 0 | 4 |
_aTumor Necrosis Factor Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aUstekinumab _xadministration & dosage |
| 700 | 1 | _aGladman, Dafna D | |
| 700 | 1 | _aChakravarty, Soumya D | |
| 700 | 1 | _aKafka, Shelly | |
| 700 | 1 | _aKaryekar, Chetan S | |
| 700 | 1 | _aYou, Yin | |
| 700 | 1 | _aCampbell, Kim | |
| 700 | 1 | _aSweet, Kristen | |
| 700 | 1 | _aKavanaugh, Arthur | |
| 700 | 1 | _aGensler, Lianne S | |
| 773 | 0 |
_tRMD open _gvol. 6 _gno. 1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/rmdopen-2019-001149 _zAvailable from publisher's website |
| 999 |
_c30777871 _d30777871 |
||